伪型人类冠状病毒的构建及人群中预先存在抗体的检测。
Construction of pseudotyped human coronaviruses and detection of pre-existing antibodies in the human population.
作者信息
Jiang Qi, Wu Xi, Dong Fangyu, Qiao Shan, Shi Qiaoyun, Jian Changyong, Chen Chen, Zhou Jiuyue, Wang Youchun, Huang Weijin
机构信息
Division of HIV/AIDS and Sex-transmitted Virus Vaccines, Institute for Biological Product Control, National Institutes for Food and Drug Control (NIFDC), State Key Laboratory of Drug Regulatory Science, Beijing 102629, China.
Department of Research & Development, Taibang Biologic Group, Beijing 100125, China.
出版信息
Biosaf Health. 2024 Sep 3;6(5):279-285. doi: 10.1016/j.bsheal.2024.09.002. eCollection 2024 Oct.
In order to clarify the pre-exist immunity background of different human coronaviruses (HCoV), this study investigated the positive rate of spike (S) protein antibodies of HCoV, including HCoV- severe acute respiratory syndrome (SARS) -associated coronavirus (SARS-CoV-1), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), Middle East respiratory syndrome coronavirus (MERS-CoV), HCoV-229E, HCoV-NL63, HCoV-HKU1 and HCoV-OC43, before and after the Coronavirus Disease 2019 (COVID-19) outbreak. We utilized pseudotyped virus-based neutralization assays (PBNA) or enzyme-linked immunosorbent assays (ELISA) to detect antibody levels against HCoV in serum samples collected in 2009-2010 and 2023. The PBNA results showed that neutralizing antibodies against SARS-CoV-1 and the MERS-CoV were negative. In the serum samples from 2009 to 2010, neutralizing antibodies against SARS-CoV-2 (D614G) were negative, whereas in the serum samples from 2023, 73 samples (73 %) showed neutralizing reactions with the SARS-CoV-2 D614G strain, 96 samples (96 %) with the BA.5 strain, and 91 samples (91 %) with the BF.7 strain. Among pre-COVID-19 samples, 33 % (33/100) showed neutralizing reactions with HCoV-229E and 63 % (63/100) with HCoV-NL63. Among post-COVID-19 samples, 50 % (50/100) showed neutralizing reactions with HCoV-229E and 49 % (49/100) with HCoV-NL63. Due to the different receptors of alpha coronavirus genus compared to other beta coronavirus genus, neutralizing antibodies against HCoV-OC43 and HCoV-HKU1 virus cannot be detected by constructing corresponding pseudotyped virus. Binding antibodies against HCoV-OC43 and HCoV-HKU1 virus were detected using ELISA. The results revealed that among pre-COVID-19 samples, 83 % (83/100) and 45 % (45/100) had binding activity with HCoV-OC43 and HCoV-HKU1, respectively. Among post-COVID-19 samples, 100 % (100/100) and 81 % (81/100) had binding activity with HCoV-OC43 and HCoV-HKU1, respectively.
为了阐明不同人类冠状病毒（HCoV）的既往免疫背景，本研究调查了2019冠状病毒病（COVID-19）疫情前后HCoV的刺突（S）蛋白抗体阳性率，包括严重急性呼吸综合征（SARS）相关冠状病毒（SARS-CoV-1）、严重急性呼吸综合征冠状病毒2（SARS-CoV-2）、中东呼吸综合征冠状病毒（MERS-CoV）、HCoV-229E、HCoV-NL63、HCoV-HKU1和HCoV-OC43。我们利用基于假型病毒的中和试验（PBNA）或酶联免疫吸附试验（ELISA）检测2009 - 2010年和2023年采集的血清样本中针对HCoV的抗体水平。PBNA结果显示，针对SARS-CoV-1和MERS-CoV的中和抗体为阴性。在2009年至2010年的血清样本中，针对SARS-CoV-2（D614G）的中和抗体为阴性，而在2023年的血清样本中，73份样本（73%）对SARS-CoV-2 D614G毒株呈现中和反应，96份样本（96%）对BA.5毒株呈现中和反应，91份样本（91%）对BF.7毒株呈现中和反应。在COVID-19之前的样本中，33%（33/100）对HCoV-229E呈现中和反应，63%（63/100）对HCoV-NL63呈现中和反应。在COVID-19之后的样本中，50%（50/100）对HCoV-229E呈现中和反应，49%（49/100）对HCoV-NL63呈现中和反应。由于α冠状病毒属与其他β冠状病毒属的受体不同，通过构建相应的假型病毒无法检测到针对HCoV-OC43和HCoV-HKU1病毒的中和抗体。使用ELISA检测针对HCoV-OC43和HCoV-HKU1病毒的结合抗体。结果显示，在COVID-19之前的样本中，分别有83%（83/100）和45%（45/100）与HCoV-OC43和HCoV-HKU1具有结合活性。在COVID-19之后的样本中，分别有100%（100/100）和81%（81/100）与HCoV-OC43和HCoV-HKU1具有结合活性。
Zotero 插件